MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

Category Primary study
JournalClinical Lymphoma, Myeloma and Leukemia
Year 2020
This article has no abstract
Epistemonikos ID: f44f33e2db97c0d131dc13bb6731043c135ddb1b
First added on: Feb 12, 2025